S6-07 Comparison of 12 weeks neoadjuvant nab
Transcription
S6-07 Comparison of 12 weeks neoadjuvant nab
undefined S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER: WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz Slide 1 / 20 Slide 2 / 20 Page 1 undefined S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER: WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz Slide 3 / 20 Slide 4 / 20 Page 2 undefined S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER: WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz Slide 5 / 20 Slide 6 / 20 Page 3 undefined S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER: WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz Slide 7 / 20 Slide 8 / 20 Page 4 undefined S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER: WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz Slide 9 / 20 Slide 10 / 20 Page 5 undefined S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER: WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz Slide 11 / 20 Slide 12 / 20 Page 6 undefined S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER: WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz Slide 13 / 20 Slide 14 / 20 Page 7 undefined S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER: WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz Slide 15 / 20 Slide 16 / 20 Page 8 undefined S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER: WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz Slide 17 / 20 Slide 18 / 20 Page 9 undefined S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER: WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz Slide 19 / 20 Slide 20 / 20 Page 10